Press Releases

Press Releases

April 26, 2018

Results to be presented show significant reduction in triglyceride levels associated with reductions of pancreatitis and burden of disease in patients with FCS CAMBRIDGE, Mass. and LAS VEGAS , April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.

April 26, 2018

Webcast scheduled for Thursday, May 3rd at 4:30 p.m. Eastern Time CAMBRIDGE, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Thursday, May 3 rd at 4:30 p.m.

April 21, 2018

Two oral presentations further demonstrate inotersen’s impact on efficacy and safety and on patient quality of life CAMBRIDGE, Mass. , April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

April 17, 2018

CAMBRIDGE, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today announced that, following today’s close of the transaction licensing Akcea the exclusive, worldwide rights to inotersen and AKCEA-TTR-L Rx , Sarah Boyce

April 17, 2018

  Akcea shareholders approved the transaction on April 16 at a Special Meeting of Stockholders                              Ionis licenses Akcea worldwide rights to inotersen and AKCEA-TTR-L Rx                CAMBRIDGE, Mass. and CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) --  Akcea

March 26, 2018

- Advocates Designate First Friday in November as FCS Awareness Day - CAMBRIDGE, Mass. , March 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat people with serious and rare

March 26, 2018
Continued benefit with long-term inotersen treatment observed in both quality of life (Norfolk-QOL-DN) and neuropathy (mNIS+7) measures in hATTR amyloidosis patients; Cardiac benefit with inotersen treatment observed in a Phase 2 study in patients with wild-type and hereditary ATTR cardiomyopathy
March 21, 2018
LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) Ltd today announced that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), for the
March 15, 2018
Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year Ionis Chief Business Officer Sarah Boyce will join
March 12, 2018
CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), and Ionis Pharmaceuticals, Inc. , today announced the presentation of a poster summarizing results from the completed Phase